Cellebrite DI (CLBT) Net Income towards Common Stockholders (2020 - 2025)

Cellebrite DI's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $21.3 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders rose 10.34% year-over-year to $21.3 million in Q4 2025; TTM through Dec 2025 was $78.3 million, a 127.68% increase from a year earlier, with the FY2025 full-year figure at $77.8 million, up 127.5% from the prior year.
• Net Income towards Common Stockholders grew to $21.3 million in Q4 2025 per CLBT's latest filing, from $20.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $55.4 million in Q1 2022 and bottomed at -$207.1 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is $8.0 million (2021), against an average of -$4.7 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 1655.96% in 2021 and plunged 3286.05% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $51.9 million in 2021, then sank by 86.35% to $7.1 million in 2022, then sank by 306.94% to -$14.6 million in 2023, then soared by 231.56% to $19.3 million in 2024, then increased by 10.34% to $21.3 million in 2025.
• Per Business Quant, the three latest CLBT Net Income towards Common Stockholders figures stand at $21.3 million (Q4 2025), $20.2 million (Q3 2025), and $19.5 million (Q2 2025).